List of the 100 largest Immunology Venture Capital Investors [2025]

List of 5 large Immunology Venture Capital Investors

In the following, we are highlighting five different interesting venture capital investors from our keyword crawler-based list that are covering immunology keywords on their websites.

1. Viva BioInnovator (China)

Viva BioInnovator, a Shanghai-based venture capital firm, specialises in early-stage investments within the biopharmaceutical sector. Over the past 12 months, VBI has focused its investments on biotechnology and pharmaceutical companies. Notable recent investments include DEKA Biosciences and i2O Therapeutics, both operating within the drug discovery industry. These activities underscore VBI’s commitment to advancing innovations in biotechnology and pharmaceuticals.

2. Wellington Partners (Germany)

Since 1998 the company Wellington Partners has invested €590M in life science companies across 58 investments. Their investments typically range from €2M to €20M. Wellington Partners especially targets companies with an experienced management team and products that are in or close to clinical trials. One of these companies, for example, is Atopix. Atopix Therapeutics is developing small-molecule drugs to treat inflammatory and respiratory diseases.

3. Sofinnova Partners (France)

Established in 1972, the company has 50 years of experience in investment under their belt. Sofinnova Partners has backed over 500 companies and has €2.5Bn assets under management. The company mainly focuses on health tech start-ups, including Ablynx NV which developed Nanobodies®, meaning an antibody-derived therapeutic protein that can be used for a range of diseases including inflammation, hematology, and oncology.

4. Pureos Partners AG (Switzerland)

Pureos Partners AG, operating under the name Pureos Bioventures, is a Swiss venture capital firm specialising in innovative drug development companies, with a particular emphasis on immunology.Over the past 12 months, Pureos has made notable investments in this sector. In late 2023, Pureos led a CHF 25 million Series C financing round for Memo Therapeutics AG, a biotech company developing therapeutic antibodies. The objective of this investment is to facilitate the completion of Phase II clinical development of AntiBKV, an antibody designed to target BK polyomavirus infections in kidney transplant patients. These infections present a significant risk to graft function and patient survival. In addition, Pureos participated in a CHF 15.5 million seed financing round for Engimmune Therapeutics AG, a Swiss biotech firm specialising in T-cell receptor TCR-based therapies for cancer treatment. Engimmune’s proprietary platform integrates advanced technologies such as genome editing, functional screening, deep sequencing, and machine learning to engineer highly specific and potent TCR therapies.

5. Column Group (USA)

The Column Group, a US-based venture capital firm specialising in life sciences, has demonstrated a strong commitment to the immunology sector over the recent months. In September 2024, their portfolio company, Synthekine, received US FDA Fast Track Designation for its investigational therapy, SYNCAR-001 combined with STK-009, targeting lupus without lymphodepletion. In addition, in August 2024, Tr1X, another company supported by TCG, announced FDA clearance of its IND application for TRX103, an allogeneic engineered Tr1 Treg cell therapy for the treatment of refractory Crohn’s disease.